Key Highlights:
- Annual Recurring Revenue up 75% to £28.8m at 30 June 2026
- Record order book of £43.7m, with 91% visibility on FY2026 revenue consensus
- H1 2026 revenue up 20% to £17.5m and adjusted EBITDA improved to £1.1m
- FY2025 statutory profit before tax of £302,000, a return to profit
- Cash fell 42% in FY2025 due to extended pharma customer payment terms
Diaceutics Plc (LSE:DXRX) has spent the past year converting one-off pharmaceutical consulting work into subscription-style contracts, and the numbers now show it. On 29 July 2026 the Belfast-founded precision medicine data company reported annual recurring revenue of £28.8m at 30 June, up 75% on a year earlier, alongside a record £43.7m order book and 91% visibility on its full-year revenue target.
The key question is whether that recurring base can carry the group from a marginal profit in 2025 to the sustained cash generation its board has promised. Interim results due in late September 2026 will give the first detailed answer. At around 145p, with a Market Value of roughly £123m, Diaceutics remains a small-cap many London investors have yet to examine closely.
H1 2026 trading update: ARR up 75% and 91% revenue visibility
The 29 July 2026 update covered the six months to 30 June 2026. Revenue rose 20% to £17.5m (22% at constant currency) from £14.6m, and adjusted EBITDA improved to £1.1m from £0.1m. Gross Margin recovered to 87% from 83%.
The headline figure was annual recurring revenue of £28.8m ($38.2m), compared with £16.4m a year earlier, up 75% reported and 69% at constant currency. The order book stood at £43.7m, up 38%, of which £15.7m is contracted for the second half of 2026. Net revenue retention climbed to 146% from 118%, gross ARR churn halved to 9%, and recurring revenue now accounts for 61% of trailing twelve-month sales.
Cash rose to £8.1m from £7.3m at 31 December 2025, with no Debt and a £2.0m undrawn facility. Contracted revenue plus weighted pipeline gave 91% visibility on the median analyst consensus of £46.7m for FY2026 revenue. Chief executive Ryan Keeling said he was “more confident than ever in Diaceutics and the long-term value we can create for shareholders”, adding that “customers are staying longer, expanding relationships and committing through recurring contracts.” Separately, on 20 August 2026 Diaceutics and the Precision Cancer Consortium, a pharmaceutical industry coalition, launched a study of up to 20 next-generation sequencing assays across US laboratories; no financial terms were disclosed.
Diaceutics helps pharmaceutical and biotechnology companies find patients eligible for targeted, diagnostic-driven therapies and get those therapies adopted faster. Its DXRX platform combines laboratory testing data, real-world healthcare information and AI-enabled analytics to show where testing is happening, which physicians treat eligible patients, and where care pathways lose them.
FY2025 revenue split into Insight and Engagement Solutions (£28.6m), covering platform subscriptions such as Lab Segmentation, Testing Rates Tracker and Physician Engage, now integrated with Epic electronic medical records; and Scientific and Advisory Services (£9.9m), covering consulting and market access studies.
The newest layer is PMx, an embedded commercialisation Partnership across a drug’s launch. The first PMx agreement was expanded in 2025 to a contract value of up to £13.0m running to September 2028, and a second, with a US biotech, was signed in late 2025. North America contributed £35.8m, or 93%, of FY2025 revenue. Diaceutics served 53 customers across 95 therapeutic brands at the end of 2025, including 18 of the top 20 global pharmaceutical companies, from offices in Jersey City, New Jersey and Belfast.
FY2025 results: back to profit, but cash fell
Final results for the year to 31 December 2025, published on 26 May 2026, showed revenue of £38.4m, up 20% (24% at constant currency). Adjusted EBITDA rose 80% to £7.6m, a 20% margin. Operating profit was a slim £43,000 against a £2.5m loss in 2024, and profit before tax was £302,000 versus a £1.9m loss. Basic Earnings Per Share turned positive at 0.11p from a 2.02p loss. No Dividend was declared. Gross margin slipped to 82% from 88% after £2.0m of data for new disease areas was expensed. ARR closed the year at £20.0m, up 19%, and the order book at £38.9m, up 56%.
The weak spot was cash, which fell 42% from £12.7m to £7.3m. Operating Activities generated £2.2m, but the group invested £6.4m in intangibles, chiefly platform and data development, and spent £0.47m on early-stage US Acquisition fees. Finance director Nick Roberts blamed “the back end phasing of revenue in the year and a broad push across all top 20 global pharma companies to extend their Credit terms”. Directors confirmed the Going Concern basis to the end of 2028, citing “significant headroom in the minimum cash balance”.
What could drive the stock next?
The immediate catalyst is the interim results, expected in late September 2026, which will show whether H1 adjusted EBITDA of £1.1m narrowed the first-half loss from the £3.0m pre-tax loss of H1 2025. Diaceutics typically books around 62% of annual revenue in the second half, so the £15.7m already contracted for H2 2026 matters more than any single half-year figure.
Beyond that, the company guided in January 2026 to 25% revenue growth for the full year, and management has identified a PMx pipeline of 24 potential customers, eight already engaging. The board has also flagged selective US M&A as a priority, having already incurred advisory costs, so a bolt-on acquisition is plausible, and the 2025 data Investment in non-precision-medicine disease areas is intended to widen the addressable market.
Customer concentration is the most obvious exposure. Diaceutics sells almost exclusively to large pharmaceutical companies and derives 93% of revenue from North America, leaving it sensitive to US drug-industry budget cycles and to the dollar-sterling rate, which has already trimmed reported growth by several points.
Cash conversion is the second concern. The 2025 squeeze from extended payment terms showed how quickly a £12.7m balance can shrink, and capitalised development of around £6m a year absorbs most operating cash flow. Any M&A would need funding from the £8.1m balance, the £2.0m Facility or new equity.
Statutory profitability remains thin: an operating profit of £43,000 on £38.4m of revenue leaves little room for a delayed contract. The PMx model concentrates large contract values with few partners, so losing one would show in ARR. And the 91% visibility figure includes weighted pipeline, not just contracted work.
Diaceutics (LSE:DXRX) enters the second half of 2026 with a much stronger recurring revenue base, a record order book and a modest cash buffer, but a statutory profit only just above breakeven. The September interim results will show how much of the 75% ARR growth has reached the income statement and whether working Capital has normalised.
Investors should track second-half delivery against the £15.7m already booked, new PMx signings, cash at 31 December 2026 and any US acquisition. If the company meets its 25% growth target while holding cash steady, the shift from consultancy to data platform will be far easier to demonstrate; if cash slips again, the market is likely to focus on funding rather than growth.






Please wait processing your request...